RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.69
−2.31%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.05
- Revenue estimate
- $1.1M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.07
- Revenue actual
- $909.0K
- Revenue estimate
- $703.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 4
- Avg surprise (4Q)
- +6.6%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.07 | -$0.05 | Beat 31.03% | $909.0K |
| May 14, 2026 | -$0.08 | -$0.08 | In line | $563.0K |
| Mar 30, 2026 | -$0.08 | -$0.08 | Miss -4.62% | $238.0K |
| Nov 13, 2025 | -$0.08 | -$0.08 | In line | $266.0K |
| Aug 14, 2025 | -$0.08 | -$0.08 | In line | $422.0K |
| May 15, 2025 | -$0.08 | -$0.08 | In line | $197.0K |
| Mar 31, 2025 | -$0.13 | -$0.12 | Beat 7.69% | $43.0K |
| May 10, 2024 | -$0.14 | -$0.07 | Beat 50.00% | — |
| Nov 13, 2023 | -$0.30 | -$0.27 | Beat 10.00% | — |
| Aug 16, 2023 | -$0.25 | -$0.22 | Beat 12.00% | — |
| May 15, 2023 | -$0.25 | -$0.36 | Miss -44.00% | — |
| Mar 2, 2023 | -$0.26 | -$0.23 | Beat 11.54% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026